MoneyWorks4Me

USFDA completes PAI at Aurobindo Pharma’s Unit VII in Telangana

05 Aug 2023 Evaluate

The United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) at Aurobindo Pharma’s Unit VII, a Formulation Manufacturing facility situated at Jedcherla Mandal, Mahaboob Nagar District, Telangana, from July 28 to August 4, 2023. The inspection closed with zero observations and a classification of No Action Indicated (NAI).

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1648.30 17.30 (1.06%)
28-Aug-2026 15:15 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1920.00
Dr. Reddys Labs. 1176.00
Cipla 1418.00
Lupin 2178.00
Zydus Lifesciences 1184.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: